180
Participants
Start Date
June 30, 2010
Primary Completion Date
August 27, 2018
Study Completion Date
August 27, 2018
Tissue Plasminogen Activator (Alteplase)
0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
Placebo
placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Auckland Hospital, Auckland
Royal North Shore Hospital, St Leonards
Westmead Hospital, Westmead
Gosford Hospital, Kanwal
Western Hospital, Footscray
Royal Melbourne Hospital, Melbourne
Epworth Healthcare, Richmond
Box Hill Hospital, Box Hill
Monash Medical Centre, Clayton
Geelong Hospital, Geelong
Royal Brisbane & Women's Hospital, Brisbane
Sunshine Coast University Hospital, Nambour
Royal Adelaide Hospital, Adelaide
Flinders Medical Centre, Bedford Park
Lyell McEwin Hospital, Elizabeth Vale
Royal Perth Hospital, Perth
St. Vincent's Hospital, Sydney
Sir Charles Gairdner Hospital, Nedlands
John Hunter Hospital, Newcastle
Gold Coast University Hospital, Gold Coast
Austin Hospital, Heidelberg
Helsinki University Central Hospital, Helsinki
Lead Sponsor
Collaborators (1)
Commonwealth Scientific and Industrial Research Organisation, Australia
OTHER_GOV
University of Melbourne
OTHER
Melbourne Health
OTHER
The Florey Institute of Neuroscience and Mental Health
OTHER
Neuroscience Trials Australia
OTHER